Page 3 - Johnson & Johnson

EU approves new one-dose J&J Covid-19 vaccine production site

The European Medicines Agency has approved a new manufacturing site for Johnson & Johnson's COVID-19 vaccine, in a move that should boost production of the one-dose vaccine across the 27-nation EU. In a statement Friday, the EU drug regulator said the new site in Anagni, Italy, will finish manufacturing of the J&J vaccine, which was licensed for use in adults across Europe in March. Production problems have stalled J&J's roll-out across the European Union in recent months and millions of doses made at a U.S. factory had to be thrown out after contamination issues. The EU has ordered 200 million doses of the J&J vaccine and was expecting 55 million by the end of June; to date, fewer than 14 million doses have been distributed. J&J's vaccine roll-out was also stalled after the EMA concluded there was a possible link between the coronavirus shot and very rare blood clots and recommended that a warning should be added to the label. Health officials say the vaccine's ...

World Coronavirus Dispatch: Virus rips through Southeast Asian workers

The case for widespread use of sniffing dogs to detect Covid, Britain's PM Johnson hints at delay to end of lockdown, and other pandemic-related news across the globe

Maldives gives emergency approval to Moderna, J&J Covid-19 vaccines

The Maldives Food and Drug Administration (MFDA) has given emergency approval to the Covid-19 vaccines by Moderna and Johnson & Johnson as the island nation continues to battle the third wave of the pandemic.

Weary seafarers come ashore in US for J&J one-dose Covid vaccine shots

It is the preferred vaccine for maritime workers because they're often docked for just a day or two at a port.

Govt looking into securing part of J&J vaccines for Indian market: Report

Johnson and Johnson's COVID-19 vaccine to be manufactured in India by Biological E cannot be directly channelled to the domestic market and will have to be handed over entirely to the US pharma giant as agreed by the firms but the government is looking at the possibility of securing a part of this production, sources said. Hyderabad-based Biological E has, however, proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for the Indian market by December and has sought "funding support" from the government. Its vaccine candidate is currently in phase 1/2 clinical trial phase. According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies. The Ministry of External Affairs (MEA), along with the Department of Biotechnology (DBT), ..

Centre steps in after foreign Covid-19 vaccine makers say no to state govts

Union govt in direct talks with firms but order book full for now

J&J to resume rollout of Covid-19 vaccine in Europe with safety warning

(Reuters) -Johnson & Johnson said on Tuesday it will resume rolling out its COVID-19 vaccine in Europe after the region's medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.

J&J reports $100 million in vaccine sales as results top forecasts

The United States is also reviewing a handful of potential cases of severe side effects in addition to those that led to the pause

Govt fast-tracks Covid-19 fight, to start vaccination for 18+ from May 1

States allowed to procure directly from manufacturers; open market supply permitted

From Sputnik V to Moderna, here's a snapshot of Covid-19 vaccines

Of this list, Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the aforementioned criteria

Decision in 3 working days after foreign Covid-19 vaccine firms apply

Many vaccine makers in talks with govt as India wants a portfolio of products

J&J delay slows Covid-19 vaccine rollout across a world needing shots

At a briefing Tuesday, FDA officials said the length of the pause will depend on what they learn, but they expect it to be a "matter of days"

India fast-tracks emergency use of foreign-made Covid-19 vaccines

No need for prior local clinical trials for vaccines cleared by regulators

S&P 500 opens nearly flat after strong inflation data; J&J slips

(Reuters) - The S&P 500 opened nearly flat on Tuesday as data showed consumer prices increased by the most in more than 8-1/2 years in March, while Johnson & Johnson slipped as federal health agencies recommended pausing the use of its COVID-19 vaccine.

J&J says in talks with Indian govt for trial of single-dose vaccine

J&J has a deal with Indian firm Biological E Ltd to contract-manufacture its vaccine

Confident of meeting US standards: Supplier of Johnson & Johnson vaccine

Johnson and Johnson (J & J) vaccine supplier Emergent BioSolutions said in a statement that it acknowledges it botched a batch of vaccines but is confident of its ability to meet US government safety requirements and standards.The statement comes a day after Johnson & Johnson reported on Wednesday that it found 15 million doses of vaccines to be unusable due to a human error in an Emergent Biosolutions' plant in the city of Baltimore, as reported by Sputnik."A single batch of drug substance was identified that did not meet specifications and our rigorous quality standards. We isolated this batch and it will be disposed of properly," the statement said on Thursday. "Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process.""We are pleased we have met our commitment to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more ..

15 million doses of J&J coronavirus vaccine ruined in US by 'human error'

Errors at a manufacturing plant in the US has ruined 15 million potential doses of the Johnson & Johnson Covid-19 vaccine, The New York Times reported.

Johnson & Johnson coronavirus vaccine batch fails quality standards check

A batch of Johnson and Johnson's COVID-19 vaccine failed quality standards and can't be used, the drug giant has said. The drugmaker didn't say how many doses were lost, and it wasn't clear how the problem would impact future deliveries. A vaccine ingredient made by Emergent BioSolutions -- one of about 10 companies that Johnson and Johnson is using to speed up manufacturing of its recently approved vaccine -- did not meet quality standards, J&J said on Wednesday. J&J said the Emergent BioSolutions factory involved had not yet been approved by the US Food and Drug Administration to make part of the vaccine. Emergent declined to comment. J&J had pledged to provide 20 million doses of its vaccine to the US government by the end of March, and 80 million more doses by the end of May. Its statement on the manufacturing problem said it was still planning to deliver 100 million doses by the end of June and was "aiming to deliver those doses by the end of May". President Joe Biden

Johnson & Johnson to give Africa 400 million Covid-19 vaccines

Johnson & Johnson says it's agreed to provide up to 400 million doses of its one-dose COVID-19 vaccine to African countries, starting this summer. The drugmaker said under its agreement with the African Vaccine Acquisition Trust, the company will provide up to 220 million vaccine doses for the African Union's 55 member countries, with delivery beginning in the July-to-September quarter. The trust will be able to order 180 million additional doses from J&J, for a total of up to 400 million shots through 2022. The company's vaccine still must receive authorisation from regulators in the African countries, but the World Health Organization approved it for emergency use on March 12. J&J also has a tentative agreement with Gavi, the Vaccine Alliance, to help support the WHO-backed COVAX program to get COVID-19 vaccines to 190 low-and middle-income countries, many of them in Africa. Johnson & Johnson and Gavi still need to sign an advance purchase agreement to provide up to .

Johnson & Johnson CEO pay irks investors upset with opioid lawsuits fallout

(Reuters) - Johnson & Johnson is coming under fire from some investors who are raising questions about companies that give their chief executives hefty pay raises despite facing billions of dollars in legal costs over their role in the U.S. opioid crisis.